Home  >  Feik School of Pharmacy  >  Academics  >  Residency Program  >  Controversies in Clinical Therapeutics

Controversies in Clinical Therapeutics

Each resident will select a controversial topic in an area of interest to present in the Controversies in Clinical Therapeutics series. The purpose of the Controversies in Clinical Therapeutics series is to effectively and concisely provide evidence-based treatment recommendations on a controversial topic after an evaluation of appropriate evidence. Other goals of this presentation include development of verbal and written communication skills and clinical reasoning.

Each month throughout the academic year, a resident from either program presents their clinically controversial topic as ACPE Continuing Education.  It is open to all interested healthcare providers and is held on the second Friday of each month from 2:00 to 4:00 PM at the University of the Incarnate Word Feik School of Pharmacy (FSOP) media room (room #478).  Please click on the dates below to access FSOP Residents past presentation handouts.

2017-2018

November: Dr. Jenna Snoga, PharmD: Extended Duration Thromboprophylaxis in Acutely Ill Medical Patients: More Harm than Good?

October: Dr. Rebekah Benitez, PharmD: Beyond the Monoamine Hypothesis: Unraveling the Role of Ketamine in Major Depressive Disorder

2016-2017

April: Dr. Rebekah Benitez, PharmD: Too Much of a Good Thing? A Comparison of Standard versus Extended Dual Antiplatelet Therapy following the Placement of Drug-Eluting Stents.

March: Dr. Jenna Snoga, PharmD: Non-selective Beta-Blockers in Patients with Ascites: Friend or Foe?

November: Dr. Emily Brysch, PharmD: Should Dipeptidyl Peptidase-4 (DPP-4) Inhibitors be Avoided in Patients with Heart Failure?

October: Dr. Shelley Glaess, PharmD: Clonidine as a Strategy for Discontinuing Long-term Sedation with Dexmedetomidine in Critically Ill Patients.

2015-2016

March: Dr. Shelley Glaess, PharmD: Periprocedural Management of Anticoagulation in Atrial Fibrillation: When to Burn Your Bridges.

January: Dr. Emily Brysch, PharmD: Steroid Use in Community Acquired Pneumonia: Should the Idea be "Suppressed" or Standard of Care?

November: Alireza FakhriRavari, PharmD: β-lactam/β-lactamase inhibitors for the treatment of infections caused by ESBL-producing Enterobacteriaceae.

October: Dr. Ashley Zurek, PharmD: Pharmacologic Venous Thromboembolism Prophylaxis vs. Auto-anticoagulation in Cirrhosis.

2014-2015

March: Dr. Ashley Zurek, PharmD: Are Sodium Glucose Cotransporter 2 Inhibitors Equally Effective in Hemoglobin A1c Lowering Potential?

January: Dr. Alireza FakhriRavari, PharmD: Interferon-free Treatments for Chronic Hepatitis C Genotype 1 Infection.

November: Dr. Hansita Patel, PharmD: Cefepime use for ESBL infections: Usable or Inducible?

October: Dr. Braden Adamson, PharmD: Inhaled Anticholinergic Therapy and Cardiovascular Safety.